ApprovedforusethroughO?JJ;~~\~lJ: 3766
`Receipt date: 10/17/2011
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`0MB control number.
`
`Complete if Known
`Aoolication Number
`13/005,005
`Filinq Date
`January 12, 2011
`Simon
`First Named Inventor
`Art Unit
`tbd
`Examiner Name
`tbd
`Attorney Docket Number
`ELEC-33
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`I 1
`I OF
`16
`Sheet
`
`Exa
`mine
`r lnts
`
`Cite
`No.
`
`1 .
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`11 .
`
`12.
`
`13.
`
`14.
`
`15.
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when
`appropriate), title of the item (book, magazine, journal, serial, symposium,
`catalog, etc.), date, pages, volume/issue number(s), publisher, city and/or
`country where published.
`ALBERT, et al. Deep brain stimulation, vagal nerve stimulation and transcranial
`stimulation: An overview of stimulation parameters and neurotransmitter release.
`Neuroscience and Biobehavioral Reviews 33 (2009) 1042-1060.
`AL-MUTAWALY, et al. The Effects of Pulse Configuration on Magnetic Stimulation.
`Journal of Clinical Neurophysioloay 20(5):361-370, 2003.
`AMOR, et al. Inflammation in neurodegenerative diseases. Immunology, 129 (2010),
`154-169.
`ANDERSON, et al. Decreasing Procedural Pain Over Time of Left Prefrontal rTMS
`forDepression: Initial Results from the Open-Label Phase of a Multisite Trial (OPT-
`TMS). Brain Stimul. 2009 April 1; 2(2): 88-92.
`AZIZ et al. Magnetic Stimulation of Efferent Neural Pathways to the Human
`OesophaQus. Gut 33: S53-S70 (Poster Session F218) (1992).
`AZIZ, Q. et al. Esophageal myoelectric responses to magnetic stimulation of the
`human cortex and the extracranial vagus nerve. Am. J. Physiol. 267 (Gastrointest.
`Liver Physiol. 30): G827-G835, 1994.
`BASHAM, et al. Magnetic Stimulation of Neural Tissue: Techniques and System
`Design. pp 293- 352, In: Implantable Neural Prostheses 1, Devices and Applications,
`D. Zhou and E. Greenbaum, eds., New York: SprinQer (2009).
`BORCKARDT, et al. Reducing Pain and Unpleasantness During Repetitive
`Transcranial Maanetic Stimulation. Journal of ECT 2006; 22:259-264.
`BOWTELL et al. Analytic Calculations of the E-Fields Induced by Time-Varying
`Magnetic Fields Generated by Cylindrical Gradient Coils. Magnetic Resonance in
`Medicine 44:782-790 (2000).
`BREDESEN, et al. Cell death in the nervous system. Nature 443(2006): 796-802.
`CAMERON, MH, et al. Transcutaneous Electrical Nerve Stimulation (TENS) for
`dementia. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.:
`CD004032. (2009 update).
`CARBUNARU et al. Toroidal coil models for transcutaneous magnetic stimulation of
`nerves. IEEE Transactions on Biomedical Engineering. 48 (No. 4, April 2001 ): 434-
`441.
`FAIERSTEIN et al. Coil Designs for Localized and Efficient Magnetic Stimulation of
`the Nervous System. Ph.D. Dissertation, Department of Biomedical Engineering,
`Case Western Reserve, May, 1999. (UMI Microform Number: 9940153, UMI
`Company, Ann Arbor Ml).
`CHAE et al. A review of functional neuroimaging studies of vagus nerve stimulation
`(VNS). Journal of Psychiatric Research 37 (2003) 443-455.
`CHANG et al. Prevalence and risk factors for postoperative delirium in a
`cardiovascular intensive care unit. American Journal of Critical Care. 2008;17:567-
`
`Examiner
`Date
`01/01/2013
`iJessica Sarcione/
`Si nature
`Considered
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
`not considered. Include copy of this form with next communication to applicant.
`1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.
`This collection of information is required by CFR 1 .98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`US PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief
`Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`
`THISADDRA8EJ:Er-'{~EE!SSt:~J1~~11~Stl~W~t5Fs151~LbJED THROUGH. /J.S./
`
`LUMENIS EX1056
`Page 1
`
`

`

`ApprovedforusethroughO?JJ;~~\~lJ: 3766
`Receipt date: 10/17/2011
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`0MB control number.
`
`Complete if Known
`Aoolication Number
`13/005,005
`Filinq Date
`January 12, 2011
`Simon
`First Named Inventor
`Art Unit
`tbd
`Examiner Name
`tbd
`Attorney Docket Number
`ELEC-33
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`I 2
`I OF
`16
`Sheet
`
`16.
`17.
`
`18.
`
`19.
`20.
`
`21.
`
`22.
`
`23.
`
`24.
`
`25.
`
`26.
`
`27.
`
`28.
`
`29.
`
`30.
`
`31.
`
`32.
`
`33.
`
`34.
`
`35.
`
`575.
`CHOILEAIN et al. Cell response to suraerv. Arch Sura 2006; 141 :1132-40.
`CHOU, Michael A. et al. Tumor Necrosis Factor Inhibition Reduces the Incidence of
`Alzheimer's Disease in Rheumatoid Arthritis Patients. Program abstracts of the
`American College of Rheumatology/ Association of Rheumatology Health
`Professionals Scientific Meeting, November 8, 2010, Atlanta GA, Presentation No.
`640.
`CLARK et al. The roles of TNF in brain dysfunction and disease. Pharmacology &
`Therapeutics , 128 (Issue 3, December 2010): 519-548.
`COMPSTON et al. Multiple sclerosis. Lancet 372 (9648, October 2008): 1502-1517.
`COTELLI M et al. Transcranial magnetic stimulation improves naming in Alzheimer
`disease patients at different stages of cognitive decline. Eur J Neural. 15(12,
`2008) :1286-92.
`data sheet for Right Guard Clear Gel from Dial Corporation, 15501 N. Dial Boulevard,
`Scottsdale AZ 85260
`data sheet for Tecophlic from The Lubrizol Corporation, 29400 Lakeland Boulevard,
`Wickliffe, Ohio 44092.
`DAVEY. Magnetic Stimulation Coil and Circuit Design. IEEE Transactions on
`Biomedical Engineering, Vol. 47 (No. 11, Nov. 2000): 1493-1499.
`HSU KH, Nagarajan SS, Durand OM. Analysis of efficiency of magnetic stimulation.
`IEEE Trans Biomed Ena. 2003 Nov; 50 (11) :1276-85.
`DELEGGE. Neurodegeneration and Inflammation. Nutrition in Clinical Practice 23
`(2008) :35-41 ;
`DELITTO et al. A Study of Discomfort with Electrical Stimulation. Phys. Ther. 1992;
`72:410-424.
`ESSELLE et al. Neural stimulation with magnetic fields: Analysis of induced electric
`fields, IEEE Trans. Biomed. Eng., 39 (July 1992), pp. 693-700.
`MARROSU et al. Vagal nerve stimulation improves cerebellar tremor and dysphagia
`in multiple sclerosis. Multiple Sclerosis 2007; 13: 1200-1202.
`FEYNMAN et al. The Feynman Lectures on Physics. Volume II. Addison-Wesley
`Publ. Co. (Readina MA, 1964), paae 15-15.
`FRICCHIONE et al. Postoperative Delirium. Am J Psychiatry 165 (7, July 2008): 803-
`812.
`GEORGE et al. Mechanisms of action of vagus nerve stimulation (VNS). Clinical
`Neuroscience Research 4 (2004) 71-79.
`GLASS et al. Mechanisms Underlying Inflammation in Neurodegeneration. Cell 140
`(2010): 918-934.
`GREEN et al. Conducting polymer-hydrogels for medical electrode applications. Sci.
`Technol. Adv. Mater. 11 (2010) 014107 (13pp).
`GRIFFIN. Perispinal etanercept: Potential as an Alzheimer therapeutic. Journal of
`Neuroinflammation 2008, 5:3.
`TOBINICK. Tumour Necrosis Factor Modulation for Treatment of Alzheimer's Disease
`Rationale and Current Evidence. CNS Druas 2009; 23 (9): 713-725.
`
`Examiner
`Date
`/Jessica Sarcione/
`01/0i/2013
`Si nature
`Considered
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
`not considered. Include copy of this form with next communication to applicant.
`1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.
`This collection of information is required by CFR 1 .98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`US PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief
`Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`
`THISADDRA8EJ:Er-'{~EE!SSt:~J1~~11~Stl~W~t5Fs151~LbJED THROUGH. /J.S./
`
`LUMENIS EX1056
`Page 2
`
`

`

`ApprovedforusethroughO?JJ;~~\~lJ: 3766
`Receipt date: 10/17/2011
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`0MB control number.
`
`Complete if Known
`Aoolication Number
`13/005,005
`Filinq Date
`January 12, 2011
`Simon
`First Named Inventor
`Art Unit
`tbd
`Examiner Name
`tbd
`Attorney Docket Number
`ELEC-33
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`I 3
`I OF
`16
`Sheet
`
`36.
`
`37.
`
`38.
`
`39.
`
`40.
`
`41.
`
`42.
`
`43.
`
`44.
`
`45.
`
`46.
`
`47.
`
`48.
`
`49.
`
`50.
`
`51.
`
`52.
`
`53.
`
`54.
`
`55.
`
`GROVES et al. Vagal nerve stimulation: a review of its applications and potential
`mechanisms that mediate its clinical effects. Neurosci Biobehav Rev (2005) 29:493-
`500.
`GUSE B et al. Cognitive effects of high-frequency repetitive transcranial magnetic
`stimulation: a systematic review. J Neural Transm. 117(1,2010):105-22.
`HAASS. Initiation and propagation of neurodegeneration. Nature Medicine
`16(11,2010): 1201-1204;
`HAFLER DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL and Fukaura H. Oral
`administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in
`patients with multiple sclerosis. Ann N Y Acad Sci 1997;56:120-131.
`HAKKINEN et al. Which structures are sensitive to painful transcranial stimulation?
`Electromyogr. clin. Neurophysiol. 1995, 35:377-383.
`HALA. Pathophysiology of postoperative delirium: Systemic inflammation as a
`response to surgical trauma causes diffuse microcirculatory impairment. Medical
`Hypotheses (2007) 68, 194-196.
`HAM DY et al. Long-term reorganization of human motor cortex driven by short-term
`sensory stimulation. Nature Neuroscience 1 (issue 1, May 1998) :64-68.
`HAMDY et al. Cranial nerve modulation of human cortical swallowing motor
`pathways. Am. J. Physiol. 272 (Gastrointest. Liver Physiol. 35): G802-G808, 1997;
`HEIM BURG et al. On soliton propagation in biomembranes and nerves. PNAS vol.
`102 (no. 28, July 12, 2005): 9790-9795.
`HOVEY et al. The Guide to Magnetic Stimulation, The Magstim Company Ltd, Spring
`Gardens, Whitland, Carmarthenshire, SA34 OHR, United Kinadom, 2006.
`HU et al. Inflammation: a bridge between postoperative cognitive dysfunction and
`Alzheimer's disease. Med Hypotheses. 201 0 Apr;74(4):722-4.
`JOHNSTON et al. Cytokines and the immunomodulatory function of the vagus nerve.
`British Journal of Anaesthesia 102(4,2009): 453-462.
`KETELAER et al. Percutaneous epidural dorsal cord stimulation in multiple sclerosis.
`Acta Neurochiruraica 49 (1979): 95-101.
`KHEDR et al. Aref Electrophysiological study of vocal-fold mobility disorders using a
`maanetic stimulator. European Journal of Neuroloqy 2002, 9: 259-267.
`KHEDR et al. Dysphagia and hemispheric stroke: A transcranial magnetic study.
`Neurophysioloaie Cliniaue/Clinical Neurophysioloay (2008) 38, 235-242).
`KIM YS, et al. major player in the brain inflammation: their roles in the pathogenesis
`of Parkinson's disease. Exp Mol Med 38(2006): 333-347.
`KRAUSE P. et al. FES cycling reduces spastic muscle tone in a patient with multiple
`sclerosis. NeuroRehabilitation. 2007;22(4):335-7.
`LANG AE. Et al. Parkinson's disease. Second of two parts. N Engl J Med 339 (No.
`16, 1998): 1130-1143.
`LEVY, et al. Therapeutic Potential of Neurotrophic Factors in Neurodegenerative
`Diseases. Biodruas 2005; 19 (2): 97-127.
`LIBOFF. Signal shapes in electromagnetic therapies: a primer. pp. 17-37 in:
`Bioelectromaanetic Medicine (Paul J. Rosch and Marko S. Markov, eds.). New York:
`
`Examiner
`/Jessica Sarcione/
`Si nature
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
`not considered. Include copy of this form with next communication to applicant.
`1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.
`This collection of information is required by CFR 1 .98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`US PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief
`Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`
`Date
`Considered 01/01/2013
`
`THISADDRA8EJ:Er-'{~EE!SSt:~J1~~11~Stl~W~t5Fs151~LbJED THROUGH. /J.S./
`
`LUMENIS EX1056
`Page 3
`
`

`

`ApprovedforusethroughO?JJ;~~\~lJ: 3766
`Receipt date: 10/17/2011
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`0MB control number.
`
`Complete if Known
`Aoolication Number
`13/005,005
`Filinq Date
`January 12, 2011
`Simon
`First Named Inventor
`Art Unit
`tbd
`Examiner Name
`tbd
`Attorney Docket Number
`ELEC-33
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`I 4
`I OF
`16
`Sheet
`
`56.
`
`57.
`
`58.
`
`59.
`
`60.
`
`61.
`
`62.
`
`63.
`
`64.
`
`65.
`
`66.
`
`67.
`
`68.
`
`69.
`
`70.
`
`71.
`
`72.
`
`73.
`
`Marcel Dekker (2004).
`LIN et al. Mitochondrial dysfunction and oxidative stress in neurodegenerative
`diseases. Nature 443(2006): 787-795.
`LIU et al. On the Induced Electric Field Gradients in the Human Body for Magnetic
`Stimulation by Gradient Coils in MRI, IEEE Transactions on Biomedical Engineering
`50: (No. 7, July 2003) pp. 804-815.
`LO. Degeneration and repair in central nervous system disease. Nature Medicine
`16(11,2010) :1205-1209.
`MAKAR et al. Brain derived neurotrophic factor treatment reduces inflammation and
`apoptosis in experimental allergic encephalomyelitis. J Neural Sci. 270(1-2,2008) :70-
`6.
`MAN et al. Magnetic stimulation for the measurement of respiratory and skeletal
`muscle function. Eur Respir J 2004; 24: 846-860.
`MANGIALASCHE F. et al. Alzheimer disease: clinical trials and drug development.
`Lancet Neural. 2010 Jul;9(7) :702-16.
`MARROSU, A. et al. Vagal nerve stimulation effects on cerebellar tremor in multiple
`sclerosis. Neuroloav 65 (2005): 490.
`McCOY et al. TNF signaling inhibition in the CNS: implications for normal brain
`function and neurodegenerative disease. Journal of Neuroinflammation 2008, 5:45.
`MERRILL CA et al. Vagus nerve stimulation in patients with Alzheimer's disease:
`Additional follow-up results of a pilot study through 1 year. J Clin Psychiatry. 2006
`Auq ;67(8) :1171-8.
`MIRSHAFIEY A et al. TGF-beta as a promising option in the treatment of multiple
`sclerosis. Neuropharmacology 56(6-7, 2009) :929-36.
`NILSSON et al. Determining the site of stimulation during magnetic stimulation of the
`peripheral nerve, Electroencephalographs and clinical neurophysiology. vol 85, pp.
`253-264, 1992.
`OLNEY et al. A comparison of magnetic and electric stimulation of peripheral nerves.
`Muscle Nerve 1990:13:957-963.
`PALOP et al. A network dysfunction perspective on neurodegenerative diseases.
`Nature 443(2006): 768-773.
`patent application JP2008/081479A (Publication No. JP2009233024A), entitled Vagus
`nerve stimulation system, to YOSHIHOTO
`PECK. IADRD: Pilot Study of Thalidomide for Alzheimer's Disease Fails to Detect
`Cognitive Benefit but Finds Effect on TNF-alpha. Doctor's Guide Global Edition, July
`26, 2002.
`PEREA et al. GLIA modulates synaptic transmission. Brain Research Reviews. 63
`(Issues 1-2, May 2010) :93-102.
`PERRY. The influence of systemic inflammation on inflammation in the brain:
`implications for chronic neurodegenerative disease. Brain, Behavior, and Immunity 18
`(2004): 407-413.
`POLAK T. et al. Far field potentials from brain stem after transcutaneous vagus nerve
`stimulation: optimization of stimulation and recordinq parameters. J Neural Transm.
`
`Date
`Examiner
`/Jessica Sarcione/
`Considered 01/01/2013
`Si nature
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
`not considered. Include copy of this form with next communication to applicant.
`1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.
`This collection of information is required by CFR 1 .98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`US PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief
`Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`
`THISADDRA8EJ:Er-'{~EE!SSt:~J1~~11~Stl~W~t5Fs151~LbJED THROUGH. /J.S./
`
`LUMENIS EX1056
`Page 4
`
`

`

`ApprovedforusethroughO?JJ;~~\~lJ: 3766
`Receipt date: 10/17/2011
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`0MB control number.
`
`Complete if Known
`Aoolication Number
`13/005,005
`Filinq Date
`January 12, 2011
`Simon
`First Named Inventor
`Art Unit
`tbd
`Examiner Name
`tbd
`Attorney Docket Number
`ELEC-33
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`I s
`I OF
`16
`Sheet
`
`2009 Oct; 116(10):1237-42.
`PROLO et al. Putative Neurolmmune Mechanisms in Alzheimer's Disease:
`Modulation by Cholinergic Anti-Inflammatory Reflex (GAIR). International Journal of
`lntearative Bioloay 2007, Vol 1 (No. 2):88-95.
`RAFFERTY et al. Magnetic phrenic nerve stimulation to assess diaphragm function in
`children following liver transplantation. Pediatr Grit Care Med 2001, 2:122-126.
`RAMAIAH et al. Postoperative Cognitive Dysfunction in the Elderly. Anesthesiology
`Clin 27(2009): 485-496.
`RASMUSSEN. Postoperative cognitive dysfunction: Incidence and prevention. Best
`Practice & Research Clinical Anaesthesioloay 20(2006, No. 2): 315-330.
`RATTAY. The basic mechanism for the electrical stimulation of the nervous system.
`Neuroscience Vol. 89, No. 2, pp. 335-346, 1999.
`RUDOLPH et al. Chemokines are Associated with Delirium after Cardiac Surgery. J
`Gerontol A Biol Sci Med Sci. 2008 February 63(2): 184-189.
`RUD RA A. et al. Postoperative delirium. Indian J Grit Care Med 2006;10:235-40.
`SAUER et al. Postoperative cognitive decline. J Anesth (2009) 23:256-259.
`SAWICKI et al. Mathematical Modelling of Vagus Nerve Stimulation. pp. 92-97 in:
`Krawczyk, A. Electromagnetic Field, Health and Environment: Proceedings of
`EHE'07. Amsterdam, IOS Press, 2008.
`SCHULTZBERG et al. Inflammation in the nervous system - Physiological and
`pathophysiological aspects. Physioloay & Behavior 92 (2007) 121-128.
`SELNES et al. Neurocognitive Complications after Coronary Artery Bypass Surgery.
`Ann Neural 2005;57:615-621.
`SHAFIK, A. Functional magnetic stimulation of the vagus nerve enhances colonic
`transit time in healthy volunteers. Tech Coloproctol (1999) 3:123-12.
`SIMILOWSKI, T. et al. Cervical magnetic stimulation: a new painless method for
`bilateral phrenic nerve stimulation in conscious humans. J. Appl. Physiol. 67(4): 1311-
`1318, 1989.
`SIMS et al. Assessing the clinical utility of the magnetic stimulator for measuring
`response latencies in the laryngeal muscles. Otolaryngol Head Neck Surg 1996;
`114:761-7.
`SJOGREN et al. Cognition-enhancing effect of vagus nerve stimulation in patients
`with Alzheimer's disease: a pilot study. J Clin Psychiatry. 2002 Nov;63(11) :972-80.
`SKOVRONSKY et al. Neurodegenerative Diseases: New Concepts of Pathogenesis
`and Their Therapeutic Implications. Annu. Rev. Pathol. Mech. Dis. 1(2006): 151-70.
`SMITH et al. The pathophysiology of multiple sclerosis: the mechanisms underlying
`the production of symptoms and the natural history of the disease. Philos Trans R
`Soc Lond B Biol Sci. 1999 October 29; 354(1390): 1649-1673.
`STUCHBURY G. et al. Alzheimer associated inflammation, potential drug targets and
`future therapies. J Neural Transm. 2005 Mar; 112(3) :429-53.
`SU IH KO. Modelling the response of scalp sensory receptors to transcranial electrical
`stimulation. Med. Biol. Eng. Comput., 2002, 40, 395-401
`TERRY, Jr. Vaaus nerve stimulation: a proven therapy for treatment of epilepsy
`
`74.
`
`75.
`
`76.
`
`77.
`
`78.
`
`79.
`
`80.
`81.
`82.
`
`83.
`
`84.
`
`85.
`
`86.
`
`87.
`
`88.
`
`89.
`
`90.
`
`91.
`
`92.
`
`93.
`
`Examiner
`/Jessica Sarcione/
`Si nature
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
`not considered. Include copy of this form with next communication to applicant.
`1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.
`This collection of information is required by CFR 1 .98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`US PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief
`Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`
`Date
`Considered 01/01/2013
`
`THISADDRA8EJ:Er-'{~EE!SSt:~J1~~11~Stl~W~t5Fs151~LbJED THROUGH. /J.S./
`
`LUMENIS EX1056
`Page 5
`
`

`

`ApprovedforusethroughO?JJ;~~\~lJ: 3766
`Receipt date: 10/17/2011
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`0MB control number.
`
`Complete if Known
`Aoolication Number
`13/005,005
`Filinq Date
`January 12, 2011
`Simon
`First Named Inventor
`Art Unit
`tbd
`Examiner Name
`tbd
`Attorney Docket Number
`ELEC-33
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`I 6
`I OF
`Sheet
`
`16
`
`94.
`
`95.
`
`96.
`
`97.
`98.
`
`99.
`
`100.
`
`101.
`
`102.
`103.
`
`104.
`
`105.
`
`strives to improve efficacy and expand applications. Cont Proc IEEE Eng Med Biol
`Soc. 2009;2009:4631-4
`The web site (www) of the National Institute of Neurological Disorders and Stroke
`(ninds) of the National Institutes of Health (nih) of the United States government (gov)
`in a subdirectory (!disorders/disorder index) web paae (htm).
`TOBINICK et al. Rapid cognitive improvement in Alzheimer disease following
`perispinal etanercept administration. Journal of Neuroinflammation 2008, 5:2.
`TRACEY. Physiology and immunology of the cholinergic antiinflammatory pathway. J.
`Clin. Invest. 117(2007): 289-296.
`TRACEY. The inflammatory reflex. Nature 420(2002): 853-859.
`TRACEY. Understanding immunity requires more than immunology. Nature
`lmmunoloav 11(2010): 561-564.
`TWEEDIE D. et al. TNF-alpha Inhibition as a Treatment Strategy for
`Neurodegenerative Disorders: New Drug Candidates and Targets. Curr Alzheimer
`Res 2007, 4(4):375-8.
`WAN et al. Postoperative impairment of cognitive function in rats: a possible role for
`cytokine-mediated inflammation in the hippocampus. Anesthesiology 2007; 106:436-
`43.
`WANG et al. A three-dimensional finite element method for computing magnetically
`induced currents in tissues. IEEE Transactions on Magnetics. 30 (6, Nov. 1994):
`5015-5023.
`www.ninds.nih.aov/disorders/disorder index.htm
`XIE GL et al. Relationship between perioperative inflammatory response and
`postoperative cognitive dysfunction in the elderly. Med Hypotheses 2009;73:402-3.
`XIONG J et al. Transcutaneous vagus nerve stimulation may attenuate postoperative
`coanitive dysfunction in elderly patients. Medical Hypotheses 73 (2009) 938-941.
`ZIPP et al. The brain as a target of inflammation: common pathways link inflammatory
`and neurodegenerative diseases. Trends in Neurosciences 29 (9, 2006) 518-527.
`
`Examiner
`/Jessica Sarcione/
`Date
`Si nature
`Considered
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
`not considered. Include copy of this form with next communication to applicant.
`1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.
`This collection of information is required by CFR 1 .98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`US PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief
`Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`
`01/01/2013
`
`THISADDRA8EJ:Er-'{~EE!SSt:~J1~~11~Stl~W~t5Fs151~LbJED THROUGH. /J.S./
`
`LUMENIS EX1056
`Page 6
`
`

`

`PTO/Sb/08b (06-09)
`Approved for use through 07/31/2009. 0MB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid
`0MB control number.
`
`Complete if Known
`Aoolication Number
`13/005,005
`January 12, 2011
`Filinq Date
`Simon
`First Named Inventor
`Art Unit
`tbd
`Examiner Name
`tbd
`Attorney Docket Number
`ELEC-33
`
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`
`(Use as many sheets as necessary)
`I 1
`I OF
`Sheet
`16
`
`Exa
`mine
`r lnts
`
`Cite
`No.
`
`1 .
`
`2.
`
`3.
`
`4.
`
`5.
`
`6.
`
`7.
`
`8.
`
`9.
`
`10.
`11 .
`
`12.
`
`13.
`
`14.
`
`15.
`
`Include name of the author (in CAPITAL LETTERS), title of the article (when
`appropriate), title of the item (book, magazine, journal, serial, symposium,
`catalog, etc.), date, pages, volume/issue number(s), publisher, city and/or
`country where published.
`ALBERT, et al. Deep brain stimulation, vagal nerve stimulation and transcranial
`stimulation: An overview of stimulation parameters and neurotransmitter release.
`Neuroscience and Biobehavioral Reviews 33 (2009) 1042-1060.
`AL-MUTAWALY, et al. The Effects of Pulse Configuration on Magnetic Stimulation.
`Journal of Clinical Neurophysioloay 20(5):361-370, 2003.
`AMOR, et al. Inflammation in neurodegenerative diseases. Immunology, 129 (2010),
`154-169.
`ANDERSON, et al. Decreasing Procedural Pain Over Time of Left Prefrontal rTMS
`forDepression: Initial Results from the Open-Label Phase of a Multisite Trial (OPT-
`TMS). Brain Stimul. 2009 April 1; 2(2): 88-92.
`AZIZ et al. Magnetic Stimulation of Efferent Neural Pathways to the Human
`OesophaQus. Gut 33: S53-S70 (Poster Session F218) (1992).
`AZIZ, Q. et al. Esophageal myoelectric responses to magnetic stimulation of the
`human cortex and the extracranial vagus nerve. Am. J. Physiol. 267 (Gastrointest.
`Liver Physiol. 30): G827-G835, 1994.
`BASHAM, et al. Magnetic Stimulation of Neural Tissue: Techniques and System
`Design. pp 293- 352, In: Implantable Neural Prostheses 1, Devices and Applications,
`D. Zhou and E. Greenbaum, eds., New York: SprinQer (2009).
`BORCKARDT, et al. Reducing Pain and Unpleasantness During Repetitive
`Transcranial Maanetic Stimulation. Journal of ECT 2006; 22:259-264.
`BOWTELL et al. Analytic Calculations of the E-Fields Induced by Time-Varying
`Magnetic Fields Generated by Cylindrical Gradient Coils. Magnetic Resonance in
`Medicine 44:782-790 (2000).
`BREDESEN, et al. Cell death in the nervous system. Nature 443(2006): 796-802.
`CAMERON, MH, et al. Transcutaneous Electrical Nerve Stimulation (TENS) for
`dementia. Cochrane Database of Systematic Reviews 2003, Issue 3. Art. No.:
`CD004032. (2009 update).
`CARBUNARU et al. Toroidal coil models for transcutaneous magnetic stimulation of
`nerves. IEEE Transactions on Biomedical Engineering. 48 (No. 4, April 2001 ): 434-
`441.
`FAIERSTEIN et al. Coil Designs for Localized and Efficient Magnetic Stimulation of
`the Nervous System. Ph.D. Dissertation, Department of Biomedical Engineering,
`Case Western Reserve, May, 1999. (UMI Microform Number: 9940153, UMI
`Company, Ann Arbor Ml).
`CHAE et al. A review of functional neuroimaging studies of vagus nerve stimulation
`(VNS). Journal of Psychiatric Research 37 (2003) 443-455.
`CHANG et al. Prevalence and risk factors for postoperative delirium in a
`cardiovascular intensive care unit. American Journal of Critical Care. 2008;17:567-
`
`I Examiner
`Signature
`*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and
`not considered. Include copy of this form with next communication to applicant.
`1Applicant's unique citation designation number (optional). 2Applicant is to place a check mark here if English language Translation is attached.
`This collection of information is required by CFR 1 .98. The information is required to obtain or retain a benefit by the public which is to file (and by the
`US PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief
`Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO
`THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`LUMENIS EX1056
`Page 7
`
`

`

`PTO/Sb/08b (06-09)
`Ap